EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Alaninamide Derivatives with Drug-like Potential for Development as Antiseizure and Antinociceptive Therapies─In Vitro and In Vivo Characterization

Marcin Jakubiec, Michał Abram iD, Mirosław Zagaja, Marta Andres-Mach, Joanna Szala-Rycaj, Gniewomir Latacz, Ewelina Honkisz-Orzechowska, Szczepan Mogilski, Monika Kubacka, Małgorzata Szafarz, Krzysztof Pociecha, Katarzyna Przejczowska-Pomierny und 9 weitere

ACS Chemical Neuroscience · 2024

DOI: 10.1021/acschemneuro.4c00013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2024. Verfasst von Marcin Jakubiec und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland. Hauptthemen laut MEDLINE: Anticonvulsants, Analgesics, Seizures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the present study, a series of original alaninamide derivatives have been designed applying a combinatorial chemistry approach, synthesized, and characterized in the in vivo and in vitro assays. The obtained molecules showed potent and broad-spectrum activity in basic seizure models, namely, the maximal electroshock (MES) test, the 6 Hz (32 mA) seizure model, and notably, the 6 Hz (44 mA) model of pharmacoresistant seizures. Most potent compounds 26 and 28 displayed the following pharmacological values: ED50 = 64.3 mg/kg (MES), ED50 = 15.6 mg/kg (6 Hz, 32 mA), ED50 = 29.9 mg/kg (6 Hz, 44 mA), and ED50 = 34.9 mg/kg (MES), ED50 = 12.1 mg/kg (6 Hz, 32 mA), ED50 = 29.5 mg/kg (6 Hz, 44 mA), respectively. Additionally, 26 and 28 were effective in the ivPTZ seizure threshold test and had no influence on the grip strength. Moreover, lead compound 28 was tested in the PTZ-induced kindling model, and then, its influence on glutamate and GABA levels in the hippocampus and cortex was evaluated by the high-performance liquid chromatography (HPLC) method. In addition, 28 revealed potent efficacy in formalin-induced tonic pain, capsaicin-induced pain, and oxaliplatin- and streptozotocin-induced peripheral neuropathy. Pharmacokinetic studies and in vitro ADME-Tox data proved favorable drug-like properties of 28. The patch-clamp recordings in rat cortical neurons showed that 28 at a concentration of 10 μM significantly inhibited fast sodium currents. Therefore, 28 seems to be an interesting candidate for future preclinical development in epilepsy and pain indications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsAnalgesicsSeizuresAnimalsMaleRatsMiceDisease Models, AnimalRats, WistarHippocampusElectroshockNeurons

Stichwörter der Autor:innen

ADME-Tox propertiesantinociceptive activityantiseizure activityepilepsyhybrid moleculesneuropathic pain

Substanzen

AnticonvulsantsAnalgesics

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.
  • Department of Experimental Pharmacology, Institute of Rural Health, Jaczewskiego 2, 20-950 Lublin, Poland.
  • Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.
  • Department Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.
  • Department of Pharmacokinetics and Physical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.
  • Department of Animal Physiology and Pharmacology, Institute of Biological Sciences, Faculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Akademicka 19, 20-033 Lublin, Poland.

ORCID-Profile: Michał Abram, Elżbieta Wyska, Piotr Wlaź, Cameron S Metcalf, Krzysztof Kamiński

Förderung

  • Narodowe Centrum Nauki

Zitieren

APA

Jakubiec, M., Abram, M., Zagaja, M., Andres-Mach, M., Szala-Rycaj, J., Latacz, G., Honkisz-Orzechowska, E., Mogilski, S., Kubacka, M., Szafarz, M., Pociecha, K., Przejczowska-Pomierny, K., Wyska, E., Socała, K., Nieoczym, D., Szulczyk, B., Wlaź, P., Metcalf, C. S., Wilcox, K., …, & Kamiński, K. (2024). Novel Alaninamide Derivatives with Drug-like Potential for Development as Antiseizure and Antinociceptive Therapies─In Vitro and In Vivo Characterization. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.4c00013

Vancouver

Jakubiec M, Abram M, Zagaja M, Andres-Mach M, Szala-Rycaj J, Latacz G, et al. Novel Alaninamide Derivatives with Drug-like Potential for Development as Antiseizure and Antinociceptive Therapies─In Vitro and In Vivo Characterization. ACS Chemical Neuroscience. 2024. doi:10.1021/acschemneuro.4c00013

BibTeX
@article{Jakubiec2024,
  author = {Jakubiec, Marcin and Abram, Michał and Zagaja, Mirosław and Andres-Mach, Marta and Szala-Rycaj, Joanna and Latacz, Gniewomir and Honkisz-Orzechowska, Ewelina and Mogilski, Szczepan and Kubacka, Monika and Szafarz, Małgorzata and Pociecha, Krzysztof and Przejczowska-Pomierny, Katarzyna and Wyska, Elżbieta and Socała, Katarzyna and Nieoczym, Dorota and Szulczyk, Bartłomiej and Wlaź, Piotr and Metcalf, Cameron S and Wilcox, Karen and Kamiński, Rafał M and Kamiński, Krzysztof},
  title = {Novel Alaninamide Derivatives with Drug-like Potential for Development as Antiseizure and Antinociceptive Therapies─In Vitro and In Vivo Characterization},
  journal = {ACS Chemical Neuroscience},
  year = {2024},
  doi = {10.1021/acschemneuro.4c00013}
}
Kostenlos starten →